Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Antimicrobial Agents and Chemotherapy
|
December 5, 2025
The molecular basis of intrinsic resistance to azoles in <i>Rhizopus arrhizus</i>
Michaela Lackner, Stephanie Toepfer, Mikhail V Keniya, et al.
Bone Marrow Transplantation
|
November 29, 2016
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma
D Ghez, C Fortpied, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 16, 2014
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial
N Mounier, P Brice, S Bologna, et al.
Nature
|
November 8, 2016
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Daniel P Dever, Rasmus O Bak, Andreas Reinisch, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 30, 2020
Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
G Manson, P Brice, C Herbaux, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 21, 2021
Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
G Manson, P Brice, C Herbaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2017
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)
U De Giorgi, S Richard, M Badoglio, et al.
Bone Marrow Transplantation
|
December 1, 2015
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party
S P Robinson, A Boumendil, H Finel, et al.
Nature Communications
|
April 11, 2019
Gene correction for SCID-X1 in long-term hematopoietic stem cells
Mara Pavel-Dinu, Volker Wiebking, Beruh T Dejene, et al.
Nature Communications
|
December 5, 2019
Author Correction: Gene correction for SCID-X1 in long-term hematopoietic stem cells
Mara Pavel-Dinu, Volker Wiebking, Beruh T Dejene, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Antimicrobial Agents and Chemotherapy
|
December 5, 2025
The molecular basis of intrinsic resistance to azoles in <i>Rhizopus arrhizus</i>
Michaela Lackner, Stephanie Toepfer, Mikhail V Keniya, et al.
Bone Marrow Transplantation
|
November 29, 2016
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma
D Ghez, C Fortpied, N Mounier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 16, 2014
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial
N Mounier, P Brice, S Bologna, et al.
Nature
|
November 8, 2016
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Daniel P Dever, Rasmus O Bak, Andreas Reinisch, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
August 30, 2020
Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
G Manson, P Brice, C Herbaux, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 21, 2021
Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma
G Manson, P Brice, C Herbaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2017
Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)
U De Giorgi, S Richard, M Badoglio, et al.
Bone Marrow Transplantation
|
December 1, 2015
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party
S P Robinson, A Boumendil, H Finel, et al.
Nature Communications
|
April 11, 2019
Gene correction for SCID-X1 in long-term hematopoietic stem cells
Mara Pavel-Dinu, Volker Wiebking, Beruh T Dejene, et al.
Nature Communications
|
December 5, 2019
Author Correction: Gene correction for SCID-X1 in long-term hematopoietic stem cells
Mara Pavel-Dinu, Volker Wiebking, Beruh T Dejene, et al.
Page
of 10